Vertex Pharmaceuticals
Trade Vertex Pharmaceuticals 24 hours a day, five days a week on Robinhood.
Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.About VRTX
Vertex Pharmaceuticals, Inc. is a global biotechnology company, which engages in the business of discovering, developing, manufacturing, and commercializing small molecule drugs for patients with serious diseases. The firm focuses on development and commercializing therapies for the treatment of cystic fibrosis, infectious diseases including viral infections such as influenza and bacterial infections, autoimmune diseases such as rheumatoid arthritis, cancer, inflammatory bowel disease and neurological disorders including pain and multiple sclerosis.
VRTX Key Statistics
Stock Snapshot
The current Vertex Pharmaceuticals(VRTX) stock price is $481.64, with a market capitalization of 121.52B. The stock trades at a price-to-earnings (P/E) ratio of 27.39.
During the trading session on 2026-08-04, Vertex Pharmaceuticals(VRTX) shares reached a daily high of $487.72 and a low of $462.85. At a current price of $481.64, the stock is +4.1% higher than the low and still -1.2% under the high.
Trading activity shows a volume of 2.02M, compared to an average daily volume of 1.35M.
The stock's 52-week range extends from a low of $362.50 to a high of $533.67.
The stock's 52-week range extends from a low of $362.50 to a high of $533.67.
VRTX News
Vertex Pharmaceuticals VRTX reported adjusted earnings of $4.73 per share for the second quarter of 2026, missing the Zacks Consensus Estimate of $4.79. Earning...
CRISPR Therapeutics CRSP incurred second-quarter 2026 loss of 94 cents per share, which was narrower than the Zacks Consensus Estimate of a loss of $1.10. The c...
Vertex Pharmaceuticals, the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Michael Yee from UBS reiterated a Buy rating on the...
Analyst ratings
78%
of 32 ratingsMore VRTX News
Analyst Whitney Ijem of Canaccord Genuity maintained a Hold rating on Vertex Pharmaceuticals, boosting the price target to $442.00. Claim 55% Off TipRanks Unloc...
Needham analyst Joseph Stringer has maintained their neutral stance on VRTX stock, giving a Hold rating today. Unlock powerful investing tools with TipRanks Pr...
BofA analyst Tazeen Ahmad raised the firm’s price target on Vertex Pharmaceuticals (VRTX) to $605 from $600 and keeps a Buy rating on the shares. FY26 revenue g...
Updates appear automatically as they are published. Act now: the analyst who called NVIDIA in 2010 just named his top 10 AI stocks — and Vertex Pharmaceuticals...
Technology Vertex Raises 2026 Guidance, But Shares Fall For One Key Reason Licensing Vertex stock dipped late Monday after the biotech giant reported adjusted e...
Vertex raised its full year 2026 total revenue guidance to $13.1 billion to $13.2 billion from $12.95 billion to $13.1 billion previously. Embedded in this guid...
In July 2026, AbCellera Biologics announced a collaboration with Vertex Pharmaceuticals to research, develop, manufacture, and commercialize multispecific T-cel...
People also own
Similar Marketcap
This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.
Popular Stocks
This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset
Newly Listed
This list is generated by showing companies that recently went public.